ClinConnect ClinConnect Logo

Main Menu

Search for Trials
For HCPs
For Industry
Blog
Contact Us
Dark Mode
Log in Sign up
Search / Trial NCT06894992

Tegoprazan and Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment

Launched by MARIO STEFFANUS · Mar 19, 2025

Download PDF Apply for Trial

Trial Information

Current as of April 23, 2025

Not yet recruiting

Keywords

Tegoprazan Lansoprazole Peptic Ulcer Peptic Ulcer Bleeding Healing Rate

ClinConnect Summary

Peptic ulcer disease (PUD) is a condition characterized by disruption of the gastric and duodenal mucosal lining due to exposure to gastric acid or pepsin. Major causes include Helicobacter pylori infection, nonsteroidal anti-inflammatory drug (NSAID) use, gastric bypass surgery, lifestyle factors such as smoking and alcohol consumption, and genetic predisposition. PUD affects 5-10% of the global population and poses a significant healthcare burden, with prevalence rising from 6.43 million to 8.09 million cases between 1990 and 2019.

Current PUD treatment involves acid-suppressing agents a...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Subjects diagnosed with upper gastrointestinal bleeding caused by peptic ulcer through gastroscopic examination
  • Exclusion Criteria:
  • • Allergic to Tegoprazan or Lansoprazole, diagnosed with gastric or duodenal cancer, pregnant, history of H. pylori infection treatment failure, presence of comorbidities such as chronic kidney disease or decompensated liver cirrhosis, alcohol consumption, or undergoing chemotherapy.

About Mario Steffanus

Mario Steffanus is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes, the organization specializes in the design and management of clinical trials across various therapeutic areas. Leveraging a robust network of experienced researchers and cutting-edge technologies, Mario Steffanus aims to streamline trial processes, ensuring compliance with regulatory standards while prioritizing participant safety and ethical considerations. The sponsor's mission is to facilitate the development of breakthrough therapies that address unmet medical needs, ultimately contributing to the betterment of healthcare worldwide.

Locations

Jakarta, Dki Jakarta, Indonesia

Jakarta, Dki Jakarta, Indonesia

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported